First line combination therapy improves progression-free survival in advanced lung cancer
A new combination therapy for the first-line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017. “This is the first phase III trial to report on the combination of chemotherapy, antiangiogenic treatment and immunotherapy as […]
